Jingyi Yin

Jingyi Yin

Auto-generated profile, based on publicly available information

Jingyi Yin

Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2021 in ACS Nano
Verified
Journal Article
Closed access
FDFeihong Dong
Feihong Dong
JAJian An
Jian An
JZJiabin Zhang
Jiabin Zhang
JYJingyi Yin
Jingyi Yin
WGWenyu Guo
Wenyu Guo
HCHeping Cheng
Heping Cheng

8 January 2019 in Oncology Letters
Verified
Journal Article
Open access
PDF file
Haiyan WuHaiyan Wu
Haiyan Wu
LLLong Li
Long Li
ZAZhengdong Ai
Zhengdong Ai
JYJingyi Yin
Jingyi Yin
LCLi Chen
Li Chen
Pristimerin is an active compound isolated from the traditional Chinese herbs Celastraceae and Hippocrateaceae. It has been reported to exert antitumor effects under experimental and clinical conditions; however, the antitumor effects and underlying mechanisms of pristimerin in oral cancer cells have not yet been identified. In the present study, the anticancer potential of pristimerin was investigated in two oral squamous cell carcinoma (OSCC) cell lines, CAL‑27 and SCC‑25. Results demonstrated that pristimerin was toxic against the two cell lines, and exhibited inhibitory effects against proliferation. Furthermore, pristimerin exhibited a more potent anti‑proliferative activity in CAL‑27 and SCC‑25 cells than the common chemotherapy drugs cisplatin and 5‑fluorouracil. In addition, cell cycle distribution analysis revealed that G0/G1 phase arrest was induced following pristimerin treatment in CAL‑27 and SCC‑25 cells, which was strongly associated with upregulation of p21 and p27, coupled with downregulation of cyclin D1 and cyclin E. Meanwhile, pristimerin induced significant apoptosis of CAL‑27 and SCC‑25 cells, alongside decreased levels of caspase‑3 and specific cleavage of poly (ADP‑ribose) polymerase. These effects were associated with inhibition of the mitogen‑activated protein kinase/extracellular signal‑regulated kinase 1/2 and protein kinase B signaling pathways. With regards to these results, pristimerin may be considered a potent novel active substance for the treatment of OSCC.

26 August 2025 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
LLLingmeng Li
Lingmeng Li
JYJingyi Yin
Jingyi Yin
LZLing Zhang
Ling Zhang
WLWenshuai Liu
Wenshuai Liu
YNYinan Niu
Yinan Niu
LHLiyu Huang
Liyu Huang